Positive data for Zafgen's obesity candidate give indication a boost
This article was originally published in Scrip
Executive Summary
Zafgen, a biopharmaceutical firm based in Cambridge, Massachusetts, US, says its lead compound, ZGN-433, for severely obese patients, has met both its primary and secondary endpoints in a Phase Ib trial. The level of weight loss observed was close to the levels that are only exceeded by surgical intervention, according to the company.